Search results for "Tissue Distribution"

showing 10 items of 240 documents

Biochemical interaction between effects of beclomethasone dipropionate and salbutamol or formoterol in sputum cells from mild to moderate asthmatics.

2005

Background:  Several in vitro studies demonstrate that corticosteroids and long-acting β2 agonists may have a complementary and synergistic mode of action on the inflammatory processes in asthma. Methods:  Sputum was induced in 20 mild to moderate asthmatic patients and the induced sputum cells (ISC) were cultured with beclomethasone dipropionate (BDP) 10−7 M, salbutamol 10−8 M and formoterol 10−8 M either alone or in combination, BDP plus salbutamol and BDP plus formoterol, for 24 h. We measured the levels of growth macrophages-colony stimulating factor (GM-CSF), released on activation normal T cells expressed and activated (RANTES) and interleukin-8 (IL-8), in the supernatant of stimulate…

AdultMalemedicine.medical_specialtymedicine.drug_classReceptor expressionImmunologySeverity of Illness IndexGlucocorticoid receptorReceptors GlucocorticoidInternal medicineFormoterol FumaratemedicineImmunology and AllergyHumansAlbuterolDrug InteractionsTissue DistributionAnti-Asthmatic AgentsChemokine CCL5Cells Culturedbusiness.industryInterleukin-8BeclomethasoneSputumGranulocyte-Macrophage Colony-Stimulating FactorBeclometasone dipropionaterespiratory systemMiddle AgedAsthmarespiratory tract diseasesBronchodilator AgentsEndocrinologyEthanolaminesSalbutamolCorticosteroidFormoterol FumarateDrug Therapy CombinationFemaleFormoterolReceptors Adrenergic beta-2businessEx vivomedicine.drugAllergy
researchProduct

Morphologic diagnosis in neuronal ceroid lipofuscinosis.

1997

Morphologic pathology in NCL is marked by two processes, the interaction of which has not yet been completely clarified: 1) degeneration of nerve cells, foremost in the cerebral cortex, resulting in considerable cerebral atrophy in early childhood forms, likely responsible for clinical and neuroradiological findings; 2) widespread accumulation of autofluorescent lysosomal lipopigments of varying ultrastructure, the demonstration of which is still largely responsible for diagnostic recognition of an individual patient's NCL. Numerous tissues and organs are available for biopsy, among them brain (historical), rectum (still favoured by some), skeletal muscle and peripheral nerves (largely by c…

AdultPathologymedicine.medical_specialtyConjunctivaAdolescentBiopsyAutopsyAtrophyNeuronal Ceroid-LipofuscinosesBiopsyMedicineHumansTissue DistributionChildCerebral atrophyCerebral Cortexmedicine.diagnostic_testbusiness.industryInfantGeneral MedicinePigments Biologicalmedicine.diseaseLipidsmedicine.anatomical_structureCerebral cortexChild PreschoolPediatrics Perinatology and Child HealthNerve DegenerationNeuronal ceroid lipofuscinosisNeurology (clinical)Morphologic diagnosisAtrophybusinessLysosomesNeuropediatrics
researchProduct

Synthesis and evaluation of zirconium-89 labelled and long-lived GLP-1 receptor agonists for PET imaging

2020

Contains fulltext : 220838.pdf (Publisher’s version ) (Open Access) INTRODUCTION: Lately, zirconium-89 has shown great promise as a radionuclide for PET applications of long circulating biomolecules. Here, the design and synthesis of protracted and long-lived GLP-1 receptor agonists conjugated to desferrioxamine and labelled with zirconium-89 is presented with the purpose of studying their in vivo distribution by PET imaging. The labelled conjugates were evaluated and compared to a non-labelled GLP-1 receptor agonist in both in vitro and in vivo assays to certify that the modification did not significantly alter the peptides' structure or function. Finally, the zirconium-89 labelled peptide…

AgonistCancer ResearchBiodistributionmedicine.drug_class[SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/ImagingPeptide[CHIM.THER]Chemical Sciences/Medicinal Chemistry[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicineChemistry Techniques SyntheticPharmacologyRare cancers Radboud Institute for Molecular Life Sciences [Radboudumc 9]Glucagon-Like Peptide-1 Receptor030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineIn vivomedicineRadiology Nuclear Medicine and imagingTissue DistributionAmino Acid SequenceReceptorGlucagon-like peptide 1 receptorchemistry.chemical_classificationRadioisotopesRadiochemistryChemistryIn vitro toxicology030220 oncology & carcinogenesisDrug DesignIsotope LabelingPositron-Emission Tomography[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/PharmacologyMolecular MedicineZirconiumPeptidesNanomedicine Radboud Institute for Molecular Life Sciences [Radboudumc 19]Ex vivoHalf-Life
researchProduct

The nicotinic acetylcholine receptor agonist ABT-594 increases FGF-2 expression in various rat brain regions

2000

The present experiments were designed to extend previous work showing that acute intermittent (-)nicotine treatment upregulates the level of fibroblast growth factor-2 (FGF2) mRNA in several rat brain regions, by the use of the nicotinic acetylcholine receptor (nAChR) agonist ABT-594 with preferential selectivity for the alpha4beta2 nAChR subtype. ABT594 treatment led to a well-defined temporal and regional upregulation of FGF-2 mRNA. A double labelling analysis showed that the up-regulation of FGF-2 mRNA involves both neuronal and non-neuronal cells. The effects of ABT-594 on FGF-2 expression were antagonized by the preferential alpha4beta2 antagonist dihydrobetaerythroidine (DHbetaE), but…

Agonistmedicine.medical_specialtyPyridinesmedicine.drug_classBiologyRats Sprague-DawleyNicotinechemistry.chemical_compoundDownregulation and upregulationInternal medicinemedicineAnimalsTissue DistributionNicotinic AgonistsRNA MessengerIn Situ HybridizationAcetylcholine receptorNeuronsMethyllycaconitineGeneral NeuroscienceAntagonistBrainDihydro-beta-ErythroidineImmunohistochemistryRatsNicotinic acetylcholine receptorNicotinic agonistEndocrinologynervous systemchemistryAzetidinesFibroblast Growth Factor 2medicine.drug
researchProduct

Semi-physiologic model validation and bioequivalence trials simulation to select the best analyte for acetylsalicylic acid

2015

Abstract The objective of this paper is to apply a previously developed semi-physiologic pharmacokinetic model implemented in NONMEM to simulate bioequivalence trials (BE) of acetyl salicylic acid (ASA) in order to validate the model performance against ASA human experimental data. ASA is a drug with first-pass hepatic and intestinal metabolism following Michaelis–Menten kinetics that leads to the formation of two main metabolites in two generations (first and second generation metabolites). The first aim was to adapt the semi-physiological model for ASA in NOMMEN using ASA pharmacokinetic parameters from literature, showing its sequential metabolism. The second aim was to validate this mod…

AnalyteChemistry PharmaceuticalMetaboliteCmaxPharmaceutical ScienceBioequivalencePharmacologyModels BiologicalBiomarkers PharmacologicalFirst pass effectchemistry.chemical_compoundPharmacokineticsIn vivoHumansMedicineComputer SimulationTissue DistributionBiotransformationChromatographyAspirinDose-Response Relationship Drugbusiness.industryHippuratesAnti-Inflammatory Agents Non-SteroidalNONMEMDrug LiberationTherapeutic EquivalencychemistryPharmacology ClinicalSalicylic AcidbusinessAlgorithmsSoftwareEuropean Journal of Pharmaceutical Sciences
researchProduct

Controlling protein interactions in blood for effective liver immunosuppressive therapy by silica nanocapsules

2020

Immunosuppression with glucocorticoids is a common treatment for autoimmune liver diseases and after liver transplant, which is however associated with severe side-effects. Targeted delivery of glucocorticoids to inflammatory cells, e.g. liver macrophages and Kupffer cells, is a promising approach for minimizing side effects. Herein, we prepare core–shell silica nanocapsules (SiO2 NCs) via a sol–gel process confined in nanodroplets for targeted delivery of dexamethasone (DXM) for liver immunosuppressive therapy. DXM with concentrations up to 100 mg mL−1 in olive oil are encapsulated while encapsulation efficiency remains over 95% after 15 days. Internalization of NCs by non-parenchymal muri…

Apolipoprotein BCell SurvivalLiver cytologyPharmacologybehavioral disciplines and activitiesDexamethasoneNanocapsulesProinflammatory cytokine//purl.org/becyt/ford/1 [https]MiceDrug Delivery SystemsDrug StabilityNanocapsulesQuímica Coloidalmental disordersBlood plasma//purl.org/becyt/ford/1.4 [https]AnimalsHumansIMMUNOSUPPRESSIVE THERAPYTissue DistributionGeneral Materials ScienceColloidsImmunosuppression TherapybiologyClusterinChemistryCiencias QuímicasSILICA NANOCAPSULESSilicon DioxideBlood proteinsPROTEIN INTERACTIONSDEXAMETHASONELiverbiology.proteinPEGylationCytokinesCIENCIAS NATURALES Y EXACTASImmunosuppressive AgentsHeLa CellsNanoscale
researchProduct

Folate-targeted supramolecular vesicular aggregates based on polyaspartyl-hydrazide copolymers for the selective delivery of antitumoral drugs.

2010

Supramolecular vesicular aggregates (SVAs) have the advantage of combining the safe and biocompatible properties of colloidal vesicular carriers based on phospholipids with those of polymeric materials, i.e. polyaspartyl-hydrazide (PAHy) copolymers. To provide SVAs with a certain tumour selectivity, folate moieties were chemically conjugated to PAHy copolymers. Physicochemical properties (mean sizes, polydispersity index and zeta potential) of folate-targeted SVAs (FT-SVAs) loaded with gemcitabine were evaluated. The antiproliferative and anticancer activity of gemcitabine-loaded FT-SVAs was evaluated against two cancer cell lines, i.e. MCF-7 cells which over-express the folate receptor and…

AzidesMaterials sciencePolymersBiophysicsBioengineeringAntineoplastic AgentsBiocompatible MaterialsPharmacologyDeoxycytidineFlow cytometryBiomaterialsDrug Delivery SystemsFolic AcidIn vivoCell Line TumorMaterials TestingmedicineHumansTissue DistributionCytotoxicityLiposomeDrug CarriersMicroscopy Confocalmedicine.diagnostic_testMolecular StructureGemcitabineIn vitroDRUG DELIVERY POLYASPARTYLHYDRAZIDE FOLATESettore CHIM/09 - Farmaceutico Tecnologico ApplicativoMechanics of MaterialsCell cultureFolate receptorDrug deliveryCeramics and CompositesBiophysicsPeptidesBiomaterials
researchProduct

Effect of actively targeted copolymer coating on solid tumors eradication by gold nanorods-induced hyperthermia.

2020

Efforts in the field of anticancer therapy are increasingly focusing on the development of localized and selective treatments. Photothermal therapy (PTT) can lead to a spatially confined death of cancer cells, exploiting an increasing in temperature generated after UV-NIR irradiation of peculiar materials. Herein, a new actively targeted gold-based drug delivery system, named PHEA-LA-Fol-AuNRs/Iri, was explored for hyperthermia and chemotherapy colon cancer treatment. Gold nanorods were stabilized using a folate-derivative of α,β-poly(N-2-hydroxyethyl)-D,L-aspartamide (PHEA-LA-PEG-FA) as coating agent and then loaded with the antineoplastic drug irinotecan (Iri). The efficacy of empty and i…

BiodistributionColorectal cancerPolymersPharmaceutical Science02 engineering and technology030226 pharmacology & pharmacy03 medical and health sciencesMice0302 clinical medicineIn vivoCell Line TumorNeoplasmsmedicineGold nanorodsHyperthermiaPhotothermal therapySolid tumorMagnetic resonance imaging folic acidAnimalsHyperthermiaTissue DistributionNanotubesChemistryCancerHyperthermia InducedPhotothermal therapyPhototherapy021001 nanoscience & nanotechnologymedicine.diseaseIrinotecanDrug deliveryCancer cellCancer researchGold0210 nano-technologymedicine.drugInternational journal of pharmaceutics
researchProduct

Characterization and biodistribution of Au nanoparticles loaded in PLGA nanocarriers using an original encapsulation process

2021

Due to their imaging and radiosensitizing properties, ultrasmall gadolinium chelate-coated gold nanoparticles (AuNP) represent a promising approach in the diagnosis and the treatment of tumors. However, their poor pharmacokinetic profile, especially their rapid renal clearance prevents from an efficient exploitation of their potential for medical applications. The present study focuses on a strategy which resides in the encapsulation of AuNP in large polymeric NP to avoid the glomerular filtration and then to prolong the vascular residence time. An original encapsulation procedure using the polyethyleneimine (PEI) was set up to electrostatically entrap AuNP in biodegradable poly(lactic-co-g…

BiodistributionGadoliniumMetal NanoparticlesNanoparticlechemistry.chemical_elementmacromolecular substances02 engineering and technologyPolyethylene glycol01 natural sciencesPolyethylene Glycolschemistry.chemical_compoundColloid and Surface ChemistryPolylactic Acid-Polyglycolic Acid Copolymer0103 physical sciencesAnimalsTissue DistributionParticle SizePhysical and Theoretical ChemistryDrug Carriers010304 chemical physicstechnology industry and agricultureSurfaces and InterfacesGeneral Medicine021001 nanoscience & nanotechnologyRatsEncapsulation (networking)PLGAchemistryColloidal goldBiophysicsNanoparticlesGoldNanocarriers0210 nano-technologyBiotechnologyColloids and Surfaces B: Biointerfaces
researchProduct

MANOTA: a promising bifunctional chelating agent for copper-64 immunoPET

2017

International audience; Improved bifunctional chelating agents (BFC) are required for copper-64 radiolabelling of monoclonal antibodies (mAbs) under mild conditions to yield stable, target-specific imaging agents. Four different bifunctional chelating agents (BFC) were evaluated for Fab (Fragment antigen binding) conjugation and radiolabelling with copper-64. Two DOTA- (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) and two NOTA- (1,4,7-triazacyclononane-1,4,7-triacetic acid) derivatives bearing a p-benzyl-isothiocyanate group were conjugated to Fab-trastuzumab - which targets the HER2/neu receptor - and the average number of chelators attached ranged from 2.4 to 4.3 macrocycles …

BiodistributionImmunoconjugatesmedicine.drug_class[SDV.CAN]Life Sciences [q-bio]/CancerMonoclonal antibody030218 nuclear medicine & medical imaging[ SDV.CAN ] Life Sciences [q-bio]/CancerInorganic ChemistryHeterocyclic Compounds 1-RingImmunoglobulin Fab FragmentsMice03 medical and health scienceschemistry.chemical_compound0302 clinical medicineCell Line TumormedicineAnimalsHumansDOTA[ SDV.IMM ] Life Sciences [q-bio]/ImmunologyTissue DistributionChelationBifunctionalChelating AgentsRadiochemistryMammary Neoplasms ExperimentalTrastuzumabIn vitroImmunoconjugateCopper RadioisotopesBiochemistrychemistryPositron-Emission Tomography030220 oncology & carcinogenesis[SDV.IMM]Life Sciences [q-bio]/ImmunologyCopper-64
researchProduct